$SGRY

Surgery Partners Q2 Earnings Call Highlights

Surgery Partners (NASDAQ:SGRY) reported Q2 same-facility revenue up 4.9% for the first half, driven by a 0.8% case increase and 4% net revenue per case. Management said commercial payer mix fell to about 49% of Q2 net revenue, with government payments rising. The company signed agreements to sell Idaho Falls assets for about $795M gross consideration and reaffirmed 2026 guidance excluding the deal.

Original reporting
Published Aug 10, 2026, 4:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 6:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Surgery Partners Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$SGRYNeutralMed
01

Why it matters

Traders can frame the stock around (1) portfolio concentration toward outpatient/short-stay surgical cases, (2) leverage reduction from expected proceeds, and (3) uncertainty around the eventual post-close guidance update.

02

Market read

A concrete divestiture with stated gross consideration and leverage impact, paired with guidance reaffirmation excluding the sold assets, creates a tradable setup into closing and any subsequent guidance update.

03

What to watch

The payer-mix shift (commercial down, government up) and Medicaid exposure reduction post-Idaho Falls could affect reimbursement assumptions more than the headline leverage reduction.

Relevance 7/10Novelty 6/10Timing: earnings call highlights published Aug 10, ahead of Idaho Falls closing and any post-close guidance update

Background

Surgery Partners reported Q2 operating metrics and discussed payer mix, physician recruitment, and capital/liquidity, alongside a signed definitive escrow sale of Idaho Falls assets.

Company-level read

Ticker impact

$SGRYNeutralMedium confidence
Context

Surgery Partners reaffirmed 2026 guidance and disclosed a definitive escrow deal to sell Idaho Falls assets for about $795M gross consideration.

Expected impact

Moderate near-term volatility possible as investors weigh leverage reduction and portfolio concentration versus guidance update risk post-close.

Evidence & confidence

The article provides concrete deal economics ($795M gross), balance-sheet leverage impact (about 0.3 turns), and guidance reaffirmation excluding Idaho Falls, which can drive repricing ahead of closing and any subsequent guidance update.

Market effects

ASC and surgical-hospital consolidation narrative continues, with Surgery Partners signaling it will not hit its 2026 M&A investment target due to the divestiture.

Idaho Falls market operations are being transferred to Intermountain Health, potentially changing local competitive dynamics for outpatient surgical services.

Limited, as the transaction is domestic and company-specific with no direct cross-border catalyst described.

Counterpoint

The guidance is reaffirmed but explicitly excludes Idaho Falls, so the market may discount the reaffirmation until management updates guidance after closing.

Key entities

  • Surgery Partners, Inc.

    NASDAQ-listed operator of ambulatory surgery centers and surgical hospitals; subject of the earnings call highlights and Idaho Falls divestiture.

  • Intermountain Health

    Partner to which Surgery Partners will sell interests in Mountain View Hospital and Idaho Falls Community Hospital and related market operations, subject to approvals.

Related articles

$SGRYMed

Surgery Partners: Q2 Earnings Snapshot

Surgery Partners Inc. (SGRY) reported a Q2 loss of $15 million, or 12 cents per share. Adjusted earnings were 10 cents per share, and revenue was $848.9 million. The company expects full-year revenue of $3.35 billion to $3.45 billion, according to its earnings release.

$SGRYMed

Surgery Partners shares edge lower despite Q2 revenue beat

Surgery Partners (NASDAQ:SGRY) shares fell 0.71% pre-market after Q2 results were mixed. Revenue rose to $848.9M, above the $830.05M forecast, and same-facility revenue grew 5%. Adjusted EPS was $0.10 vs $0.06 consensus, but GAAP net loss was $0.12/share. Adjusted EBITDA fell to $125.2M. Company reaffirmed 2026 revenue $3.35B-$3.45B and adjusted EBITDA at least $530M.

$SGRYMedAI 8/10

Surgery Partners Q2 2026 slides show 5% revenue growth, Idaho exit

Surgery Partners (NASDAQ:SGRY) reported Q2 2026 revenue of $848.9M, above an $830.05M estimate, but posted an adjusted loss of $0.12 per share versus a $0.06 profit expectation. Same-facility revenue grew 5.0% on 4.8% rate growth. The company reaffirmed 2026 guidance: $3.35B to $3.45B revenue and at least $530M adjusted EBITDA, excluding the pending Idaho Falls divestiture.

$SGRYMedAI 8/10

Surgery Partners, Inc. (SGRY): Results of Operations and Financial Condition

Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 SURGERY PARTNERS, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS REAFFIRMS FULL YEAR 2026 GUIDANCE BRENTWOOD, Tenn., August 10, 2026 (GLOBE NEWSWIRE) - Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or t